Further good news from prophylactic human papillomavirus vaccines: Long-term duration of immunity

Women's Health

Volumn 6, Issue 3, 2010, Pages 361-363

  Paolini, Francesca ^a   Venuti, Aldo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus; Immunity persistence; Vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; NOTE; PAPILLOMAVIRUS INFECTION; PROTECTION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS IMMUNITY;

EID: 77952128950     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.18     Document Type: Note

References (13)

1. Romanowski B, de Borba PC, Naud PS et al.; GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (9706), 1975-1985 (2009).
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
3. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342-350 (2002).
4. zur Hausen H: Perspectives of contemporary papillomavirus research. Vaccine 24 (Suppl. 3), S3/III-IV (2006)
5. Franceschi S, Herrero R, Clifford GM et al.: Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int. J. Cancer 119, 2677-2684 (2006).
6. David M-P, Van Herck K, Hardt K et al.: Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modelling of sustained antibody responses. Gynecol. Oncol. 115 (Suppl. 3), S1-S6 (2009).
7. Harper DM, Franco EL, Wheeler CM et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757-1765 (2004).
8. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
9. Muñoz N, Bosch FX, Castellsagué X et al.: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111, 278-285 (2004).
10. Giannini SL, Hanon E, Moris P et al.: Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937-5949 (2006).
11. Bosch FX, Manos MM, Munoz N et al.: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl Cancer Inst. 87 (11), 796-802 (1995).
12. Koutsky LA, Ault KA, Wheeler CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347 (21), 1645-1651 (2002).
13. Venuti A, Massa S, Mett V et al.: An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 27, 3395-3397 (2009).